Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
BGT-002 in Metabolic Dysfunction Associated Steatohepatitis: NCT06491576 Clinical Landscape Report 2026
28 September 2026
NCT06491576 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Empagliflozin in Fibrosis, Liver: NCT06519448 Clinical Landscape Report 2026
28 September 2026
NCT06519448 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efruxifermin in Metabolic Dysfunction Associated Steatohepatitis: NCT06528314 Clinical Landscape Report 2026
28 September 2026
NCT06528314 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Rozanolixizumab in Myasthenia Gravis: NCT06540144 Clinical Landscape Report 2026
28 September 2026
NCT06540144 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Omeprazole in Metabolic Dysfunction Associated Steatohepatitis: NCT06539494 Clinical Landscape Report 2026
28 September 2026
NCT06539494 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
![[68Ga]Ga-DOTA-Cys-ATH001 in Metabolic Dysfunction Associated Steatohepatitis: NCT06562361 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_02_0815c5db75.jpg)
9 min read
[68Ga]Ga-DOTA-Cys-ATH001 in Metabolic Dysfunction Associated Steatohepatitis: NCT06562361 Clinical Landscape Report 2026
28 September 2026
NCT06562361 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
RD-06-04 in Granulomatosis With Polyangiitis: NCT06548620 Clinical Landscape Report 2026
28 September 2026
NCT06548620 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Efgartigimod/Hyaluronidase in Myasthenia Gravis, Ocular: NCT06558279 Clinical Landscape Report 2026
28 September 2026
NCT06558279 clinical landscape for Myasthenia Gravis, Ocular: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TLC-2716 in Hypertriglyceridemia: NCT06564584 Clinical Landscape Report 2026
28 September 2026
NCT06564584 clinical landscape for Hypertriglyceridemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nicotinamide riboside in Idiopathic Pulmonary Fibrosis: NCT06567717 Clinical Landscape Report 2026
28 September 2026
NCT06567717 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinat FGF21-Fc fusion Protein(Ampsource Biopharma) in Metabolic Dysfunction Associated Steatohepatitis: NCT06569524 Clinical Landscape Report 2026
28 September 2026
NCT06569524 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT06569381 Clinical Landscape Report 2026
28 September 2026
NCT06569381 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.